Type II Diabetes
67
7
8
41
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
13 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.5%
3 terminated out of 67 trials
93.2%
+6.7% vs benchmark
13%
9 trials in Phase 3/4
32%
13 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (67)
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The GRoceries Aimed at Increasing Nutrition Study
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes
INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling
Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment
Dietary Approaches to Stop Hypertension for Diabetes
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Effectiveness of an mHealth Mobile App
The Effects of Raspberry Leaf Tea on Blood Glucose Control
Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes
Passive Stretching Versus Electrical Stimulation on Glucose Level, in Elderly With Type II Diabetes
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults
Burger Allen Exercises in Knee OA With Type II Diabetes
Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes